CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 31 enrolled
Drug / intervention
Abiraterone Acetate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03565835
NCT03565835Phase 2Completed
CompareCT.gov

Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer

Montefiore Medical Center·interventional·Posted Jun 21, 2018·Updated Jan 26, 2026

In Brief

A Phase 2 clinical trial evaluating Abiraterone Acetate and Prednisone for Prostatic Neoplasms. Completed, enrolled 31 participants across 1 site.

Detailed Summary

The goal of this study is to find out if patients with prostate cancer being treated with the medications abiraterone and prednisone can discontinue hormone injections (examples include leuprolide, goserelin, triptorelin and degarelix). Abiraterone and prednisone are pills used to treat patients with prostate cancer. When abiraterone and prednisone are used, hormone injections are usually continued to maintain a low testosterone level in the blood. This study is being done to find out if testosterone in the blood will stay low while abiraterone and prednisone are used without continued hormone injections.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstatic Neoplasms
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJun 21, 2018
Enrollment StartJun 13, 2018
Primary CompletionNov 17, 2021
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 8.0 years ago

Interventions

Abiraterone Acetatedrug

Abiraterone Acetate with Prednisone and with Discontinuation of GnRH Analogue

Prednisonedrug

Abiraterone Acetate with Prednisone and with Discontinuation of GnRH Analogue